Theravance Biopharma (NASDAQ:TBPH) had its price objective hoisted by equities researchers at HC Wainwright from $25.00 to $30.00 in a research report issued to clients and investors on Wednesday, January 8th, The Fly reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 19.19% from the stock’s previous close.
Several other equities analysts also recently issued reports on TBPH. ValuEngine raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a report on Friday, January 3rd. Piper Jaffray Companies cut their price target on shares of Theravance Biopharma from $55.00 to $40.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. Robert W. Baird raised shares of Theravance Biopharma from an “underperform” rating to a “neutral” rating and dropped their target price for the stock from $22.00 to $18.00 in a research note on Wednesday, November 6th. Finally, BidaskClub downgraded shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $34.40.
TBPH traded down $0.29 during trading on Wednesday, hitting $25.17. The stock had a trading volume of 2,833 shares, compared to its average volume of 266,740. The firm has a market cap of $1.45 billion, a PE ratio of -6.32 and a beta of 1.85. The company has a 50 day simple moving average of $23.49 and a 200-day simple moving average of $20.22. Theravance Biopharma has a 12 month low of $15.18 and a 12 month high of $28.44.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.05). The company had revenue of $12.43 million during the quarter, compared to analyst estimates of $13.33 million. As a group, research analysts forecast that Theravance Biopharma will post -4.09 EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC acquired a new position in shares of Theravance Biopharma in the third quarter valued at approximately $32,000. Tower Research Capital LLC TRC boosted its holdings in shares of Theravance Biopharma by 68.7% in the third quarter. Tower Research Capital LLC TRC now owns 1,798 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 732 shares during the period. Simplex Trading LLC boosted its holdings in shares of Theravance Biopharma by 30.1% in the third quarter. Simplex Trading LLC now owns 5,043 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,167 shares during the period. Wolverine Trading LLC acquired a new position in shares of Theravance Biopharma in the second quarter valued at approximately $203,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of Theravance Biopharma by 117.1% in the second quarter. Cubist Systematic Strategies LLC now owns 28,969 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 15,627 shares during the period. Institutional investors own 79.64% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
